Free Trial
NASDAQ:CRGX

CARGO Therapeutics Q3 2023 Earnings Report

CARGO Therapeutics logo
$4.49 +0.01 (+0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.49 0.00 (0.00%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CARGO Therapeutics EPS Results

Actual EPS
-$37.15
Consensus EPS
-$2.38
Beat/Miss
Missed by -$34.77
One Year Ago EPS
N/A

CARGO Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CARGO Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, December 13, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

CARGO Therapeutics' Q3 2025 earnings is scheduled for Monday, August 11, 2025

CARGO Therapeutics Earnings Headlines

Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …
CRGX - Cargo Therapeutics Inc Financials | Morningstar
See More CARGO Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CARGO Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CARGO Therapeutics and other key companies, straight to your email.

About CARGO Therapeutics

CARGO Therapeutics (NASDAQ:CRGX), a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

View CARGO Therapeutics Profile

More Earnings Resources from MarketBeat